AR030257A1 - Uso de un inhibidor de proteasa serina de tipo kunitz para la fabricacion de un medicamento para acelerar la velocidad de aclaramiento mucociliar - Google Patents

Uso de un inhibidor de proteasa serina de tipo kunitz para la fabricacion de un medicamento para acelerar la velocidad de aclaramiento mucociliar

Info

Publication number
AR030257A1
AR030257A1 ARP990106690A ARP990106690A AR030257A1 AR 030257 A1 AR030257 A1 AR 030257A1 AR P990106690 A ARP990106690 A AR P990106690A AR P990106690 A ARP990106690 A AR P990106690A AR 030257 A1 AR030257 A1 AR 030257A1
Authority
AR
Argentina
Prior art keywords
protease inhibitor
serine protease
manufacture
speed
type serine
Prior art date
Application number
ARP990106690A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR030257A1 publication Critical patent/AR030257A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de un inhibidor de proteasa serina de tipo Kunitz, que es para la fabricacion de un medicamento, util para acelerar la velocidad del aclaramiento mucociliar en un sujeto comprendiendo una cantidad estimuladora del aclaramiento mucociliar efectivo del inhibidor de la proteasa serina de tipo Kunitz y un vector aceptable fisiologicamente, por ej, aprotinina o bicunina, para estimular la velocidad de aclaramiento mucociliar de moco y esputo en las vías aéreas pulmonares de sujetos afectados con disfunciones mucociliares tales como la fibrosis quística.
ARP990106690A 1998-12-22 1999-12-22 Uso de un inhibidor de proteasa serina de tipo kunitz para la fabricacion de un medicamento para acelerar la velocidad de aclaramiento mucociliar AR030257A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21891398A 1998-12-22 1998-12-22
US44196699A 1999-11-17 1999-11-17

Publications (1)

Publication Number Publication Date
AR030257A1 true AR030257A1 (es) 2003-08-20

Family

ID=26913378

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106690A AR030257A1 (es) 1998-12-22 1999-12-22 Uso de un inhibidor de proteasa serina de tipo kunitz para la fabricacion de un medicamento para acelerar la velocidad de aclaramiento mucociliar

Country Status (13)

Country Link
US (1) US20070086956A1 (es)
EP (2) EP1374891B1 (es)
JP (2) JP3819239B2 (es)
CN (1) CN1229138C (es)
AR (1) AR030257A1 (es)
AT (2) ATE407694T1 (es)
AU (1) AU758832B2 (es)
CA (1) CA2356404C (es)
DE (2) DE69912988T2 (es)
DK (2) DK1374891T3 (es)
ES (2) ES2318075T3 (es)
TW (1) TWI249406B (es)
WO (1) WO2000037099A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
CN1332715C (zh) * 2003-09-09 2007-08-22 王继峰 蛋白酶抑制剂在制备预防和治疗肺部疾病的药物中的用途
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
GB0411145D0 (en) * 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
CN100408094C (zh) * 2005-08-29 2008-08-06 吉林圣元科技有限责任公司 蛋白酶抑制剂在保护肝细胞功能中的应用
MX2009003002A (es) * 2006-09-19 2009-06-01 Discovery Lab Inc Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.
WO2013175007A1 (en) * 2012-05-25 2013-11-28 Inserm Agents for treating cystic fibrosis
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (de) * 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DE573603T1 (de) * 1991-03-01 1999-05-06 Dyax Corp., Cambridge, Mass. Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.
RU2054180C1 (ru) * 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
US5747449A (en) * 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
US5436153A (en) * 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
EP0740702A1 (en) * 1992-12-02 1996-11-06 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ATE275583T1 (de) * 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
DE69632435T2 (de) * 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
HU226419B1 (en) * 1996-03-11 2008-12-29 Aerovance Human bikunin
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance

Also Published As

Publication number Publication date
US20070086956A1 (en) 2007-04-19
DK1140150T3 (da) 2004-03-22
DE69912988T2 (de) 2004-11-11
AU758832B2 (en) 2003-04-03
AU1987800A (en) 2000-07-12
JP2006232810A (ja) 2006-09-07
CN1334743A (zh) 2002-02-06
ES2318075T3 (es) 2009-05-01
CA2356404A1 (en) 2000-06-29
EP1140150A2 (en) 2001-10-10
JP3819239B2 (ja) 2006-09-06
EP1374891A1 (en) 2004-01-02
ES2209542T3 (es) 2004-06-16
WO2000037099A3 (en) 2000-10-26
ATE407694T1 (de) 2008-09-15
CN1229138C (zh) 2005-11-30
TWI249406B (en) 2006-02-21
EP1374891B1 (en) 2008-09-10
WO2000037099A2 (en) 2000-06-29
DK1374891T3 (da) 2009-01-26
EP1140150B1 (en) 2003-11-19
ATE254473T1 (de) 2003-12-15
CA2356404C (en) 2010-03-30
JP2002532558A (ja) 2002-10-02
DE69912988D1 (de) 2003-12-24
DE69939559D1 (de) 2008-10-23

Similar Documents

Publication Publication Date Title
AR018900A1 (es) Dispositivo para determinar fases respiratorias del sueno
AR030257A1 (es) Uso de un inhibidor de proteasa serina de tipo kunitz para la fabricacion de un medicamento para acelerar la velocidad de aclaramiento mucociliar
BRPI0414425A (pt) composições farmacêuticas
EP1005485A4 (en) NOVEL PULMONARY SURFACTANTS AND THERAPEUTIC USES, INCLUDING PULMONARY WASHING
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
AR015820A1 (es) Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
WO2005020885A3 (en) Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR020760A1 (es) DISPOSITIVO PARA CONTROLAR LA ADMINISTRACIoN DE UN AGENTE ACTIVO EN AEROSOL EN LOS PULMONES DE UN PACIENTE HUMANO
CO4940408A1 (es) Composicion de aerosol farmaceutico
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
ES2194720T3 (es) Enzimas para el tratamiento de diabetes mellitus tipo i.
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
ES2172510T3 (es) Nueva combinacion de formoterol y budesonida.
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
AR039408A1 (es) Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
MX2022013195A (es) Uso de proteina surfactante d para tratar infecciones virales.
BRPI0210428B8 (pt) uso de glicoproteína para preparação de composições para o tratamento e a reepitelização de feridas
PE20030837A1 (es) Tensioactivos pulmonares que contienen una polimixina para mejorar las propiedades superficiales
BR9204815A (pt) Compsoicaos farmaceutica a base de taurina para a administracao por inalacao,e,processo de utilizacao

Legal Events

Date Code Title Description
FB Suspension of granting procedure